Chemo ID Personalized Cancer Treatment

01/20/2026

We are delighted to share that the ChemoID Team will present at this fantastic meeting organized by Total Health Oncology. We will discuss positive data on ChemoID, the only functional precision medicine diagnostic assay that has undergone rigorous testing in randomized clinical trials.

09/08/2025

ChemoID is the only functional precision medicine test to have received Breakthrough Device Designation from the FDA to diagnose drug sensitivity for glioblastoma.

09/04/2025

🎯 Watch the video to learn more about how ChemoID can optimize cancer treatment for patients, offering a more precise, efficient, and patient-centered approach to oncology care.

09/02/2025

How ChemoID is changing cancer treatment

09/01/2025

08/02/2025

05/04/2025

https://www.nature.com/articles/s41698-025-00874-0

Patients with recurrent platinum-resistant ovarian cancer (PROC) have poor clinical outcomes, owing mainly to the presence of therapy-resistant cancer stem cells (CSCs). The NCT03949283 randomized clinical trial enrolled patients with recurrent PROC to receive ChemoID-guided chemotherapy or the best...

04/15/2025

ChemoID on MSN news

https://www.msn.com/en-gb/health/other/chemoid-test-leads-to-better-outcomes-in-platinum-resistant-ovarian-cancer/ar-AA1CoBHB

04/13/2025

https://www.cell.com/cell-reports-medicine/pdf/S2666-3791(23)00135-0.pdf